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1525-0016/$Recombinant adenovirus administration gives rise to transgene-independent effects caused by the
ability of the vector to activate innate immunity mechanisms. We show that recombinant
adenoviruses encoding reporter genes trigger IFN-A and IFN-B transcription from both plasmacy-
toid and myeloid mouse dendritic cells. Interestingly, IFN-B and IFN-A5 are the predominant
transcribed type I IFN genes both in vitro and in vivo. In human peripheral blood leukocytes type I
IFNs are induced by adenoviral vectors, with a preponderance of IFN-B together with IFN-A1 and
IFN-A5 subtypes. Accordingly, functional type I IFN is readily detected in serum samples from human
cancer patients who have been treated intratumorally with a recombinant adenovirus encoding
thymidine kinase. Despite inducing functional IFN-A release in both mice and humans, gene transfer
by recombinant adenoviruses is not interfered with by type I IFNs either in vitro or in vivo. Moreover,
IFN-A does not impair replication of wild-type adenovirus. As a consequence, cancer gene therapy
strategies with defective or replicative-competent adenoviruses are not expected to be hampered
by the effect of the type I IFNs induced by the vector itself. However, type I IFN might modulate
antitumor and antiadenoviral immune responses and thus influence the outcome of gene
immunotherapy.R
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Gene therapy strategies have long overlooked the fact
that viral vectors, either defective or replicative, might be
able to induce type I interferons (IFNs). Type I IFNs are
polypeptides discovered for their ability to interfere with
viral infection of cell cultures [1]. In mice and humans
there are 13 and 17 genes, respectively, encoding IFN-a
subtypes, while there is a single gene encoding IFN-h in
both species [2]. Despite this remarkable number of
intronless genomic sequences within a single individual,
there is evidence for only one heterodimeric receptor [3].
Slight functional differences among the IFN-a subtypes
have been reported [4], but this issue remains an active
and controversial area of research. The type I IFN receptorTHERAPY Vol. 14, No. 1, July 2006
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.00induces biochemical pathways that include the activa-
tion of STAT-1, STAT-2, STAT-3, MAP kinases, PI3 kinase,
and NF-nB [3,5]. Cells exposed to IFN-a/h are set in a state
of viral resistance that depends on various effector
molecules that interfere with viral replication and protein
synthesis [1] and on increased susceptibility to the attack
of cytolytic T lymphocytes (CTLs) [6,7]. It is not surpris-
ing that viral evolution has selected many mechanisms to
escape type I interferon effects [8]. In addition to local
antiviral effects, IFN-a manages to regulate the antibody
immune response [9] and increase the activity of natural
killer cells [10]. Recently IFN-a has been found to be
involved in the presentation of antigens from peripheral
cells by dendritic cells (DC) [11]. This cross-priming129
ARTICLE doi:10.1016/j.ymthe.2006.02.015function is believed to be crucial for the CTL immune
response against viruses and possibly against tumors. It
has been recently demonstrated that the expression of
type I IFN receptor on CTL precursors is necessary for
effector differentiation [12].
When a virus causes viremia, a specialized DC sub-
population named plasmacytoid DC (pDC) is induced to
produce a high output of IFN-a and IFN-h [13,14]. In
mice these cells are CD11c+ B220+ Ly6G/C+ and mPDCA-
1+[15,16]. Other DC subpopulations are also known to
produce IFN-a in response to proper viral molecules [17].
These cells sense the presence of virus by a number of
known receptors and possibly others that remain undis-
covered. Among these, TLR-9, TLR-7, and TLR-3 detect
viral nucleic acids inside phagosomes [14], while cyto-
plasmic double-stranded RNA is detected by PKR [17] and
possibly other RNA binding proteins [18]. Systemic
treatment with type I IFNs is used clinically mainly in
the treatment of chronic viral hepatitis [19]. Other
empirical indications for this drug exist, including
malignancies and multiple sclerosis, although the mech-
anisms of action are still poorly understood.
Type I IFN induction by viral vectors could be highly
relevant for gene therapy. On the one hand, there is
potential interference with viral replication or gene
transfer, and on the other there are biological effects
from type I IFNs to be added to those set in motion by the
transgene(s) [20]. In this sense, if viral vectors were
capable of triggering IFN-a/h, their effects, both as
vaccines and as shuttles of immune system genes, would
be greatly modified. In the case of cytokine gene therapy
[20] the combined effects of the transgene expression and
the innately induced type I IFN would be of obvious
therapeutic importance [21].
In this study, we show that first-generation adenoviral
vectors induce type I IFNs both in vivo and in vitro from
myeloid DC (mDC) and pDC, even though IFN-a/h do
not modify adenoviral replication or gene transfer either
in vivo or in vitro.
RESULTS
Recombinant Adenovirus Induces IFN-A and IFN-B
Release From Murine Plasmacytoid and Myeloid DC
Cultures
In vitro culture of mononucleated mouse bone marrow
cells for 10–12 days in the presence of 100 ng/ml sFLT-3L
leads to the enrichment of DC of both plasmacytoid
(mPDCA-1+) and myeloid (mPDCA-1 CD11c+) lineages
[22]. In our cultures, CD11c+ cells routinely ranged from
40 to 70% and plasmacytoid mPDCA-1+ cells from 20 to
30% (data not shown). As shown in Fig. 1A, exposure to
recombinant adenovirus encoding enhanced green fluo-
rescent protein (EGFP) under the control of the CMV
promoter (AdCMVGFP) gave rise to induction of IFN-a
and -h mRNA in bulk cultures. When we sorted each cell130subtype sequentially to N95% purity using immunomag-
netic beads, we found that both subtypes of DC were
transcribing type I IFNs. Moreover, we found that this
phenomenon occurred in a wide range of adenoviral
m.o.i., without need for productive gene transfer of the
pDC, as documented by lack of EGFP expression in FACS
studies (Fig. 1B). By contrast, a fraction of mPDCA-1
CD11c+ mDC was transfected by AdCMVGFP (Fig. 1B).
These IFN-a and IFN-h inducing effects were independent
of the transgene encoded in the adenovirus, since they
were also observed with an adenovirus encoding h-
galactosidase (AdCMVLacZ) (data not shown).
Although we had expected a broader spectrum of
IFN-a genes to be transcribed, IFN-a5 was the one that
was earlier and more intensely expressed along with
IFN-h (Fig. 1C). The polymerase chain reaction (PCR)
cloning technique used to study the IFN-a genes has
been validated, and consequently all 16 IFN-a sequences
had an equal chance to be detected. It is of note that the
majority of IFN-a mRNA produced under baseline
conditions in DC is IFN-ap2, which has been described
as a pseudogene [23].
Type I IFN was secreted into the supernatant of these
bulk cultures and we assessed its biological activity in a
standard encephalomyocarditis virus (EMCV) protection
bioassay quantified with titered standards of commercial
mouse IFN-a (Fig. 1D).
AdCMVGFP was virtually lipopolysaccharide (LPS) free
(b0.15 EU/ml). However, to exclude the effects of other
possible contaminants in the adenovirus preparation, we
used an adenovirus encoding the HSV-TK (AdTK), which
was manufactured and quality controlled under GMP
conditions [24]. As shown in Fig. 1E, this clinical-grade
recombinant adenovirus induced the transcription of
IFN-a and -h as efficiently as AdCMVGFP tested in
parallel at the same m.o.i.
These results suggested that recombinant adenoviruses
could act as inducers of IFN-a and -h from DC and that
this mechanism, if operational in vivo, could alter the
results of gene therapy strategies involving adenoviral
vectors.
IFN-A and IFN-B Transcription is Induced by
Intravenous Injection of Recombinant Adenovirus in
Splenic Myeloid and Plasmacytoid DC
To investigate if recombinant adenovirus would induce
IFN-a and IFN-h production from DC in vivo, we used a
procedure to enrich the spleen populations of DC in vivo.
As described [25], we performed a hydrodynamic injec-
tion of a plasmid encoding the DC differentiation factor
sFLT-3L. As a result, 1 week after hydrodynamic injection
the spleen of mice contained up to 10% total DC. This
represented a homogeneous 10-fold enrichment of the
various DC populations.
We injected doses of 108 pfu AdCMVGFP or clinical
grade AdTK into these mice via the tail vein. Twenty-MOLECULAR THERAPY Vol. 14, No. 1, July 2006
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FIG. 1. IFN-a and IFN-h induction by adenovirus in murine DC. (A) Bone marrow mononuclear cells were cultured for 12 days in the presence of 100 Ag/ml sFLT-
3L giving rise to cultures containing 660% different subpopulations of DC. Bulk cultures and mPDCA-1 CD11c+ or mPDCA-1+ positively selected cells by
immunomagnetic methods were exposed to AdCMVGFP at m.o.i. 500. mRNA encoding IFN-a and IFN-h was quantified in comparison to h-actin mRNA by
quantitative RT-PCR before (white bars) and 24 h after (black bars) exposure to recombinant adenovirus. (B) EGFP expression measured by FACS analysis of
purified mPDCA-1+ DC and mDC from sFLT-3L bone marrow cultures transfected with AdCMVGFP at m.o.i. 1000. (C) IFN-a subtype mRNA amplified by PCR
from bone marrow cell culture was cloned in the TOPO TA cloning kit. DNAs from 50 single clones at 0, 6, and 24 h after exposure to AdCMVGFP were
completely sequenced and compared to reported GenBank IFN-a sequences to identify the different IFN-a subtypes. Results are expressed as the relative
frequency of clones from each IFN-a gene at each given time point. (D) Quantitative bioassay of type I IFN activity present in supernatants of sFLT-3L bone
marrow cultures at 0, 6, and 24 h after exposure to AdCMVGFP at m.o.i. 1000. (E) Experiment similar to that in A with dendritic cells in culture stimulated for 6 h
as indicated by AdCMVGFP or AdTK at m.o.i. 500. Data in A, B, and E are representative of five experiments performed independently.
ARTICLEdoi:10.1016/j.ymthe.2006.02.015four hours later we removed the spleens surgically and
extracted RNA from immunomagnetically purified
mPDCA-1+ plasmacytoid and mPDCA-1 CD11c+ mye-
loid DC. Purity was as high as 90–100% in each
separation procedure.
As can be observed in Fig. 2, both mPDCA-1
CD11c+ and mPDCA-1+ splenocytes readily transcribed
IFN-a and IFN-h mRNAs with high intensity as assessed
by quantitative RT-PCR. It is of note that levels of
mRNA expression were apparently much higher in theMOLECULAR THERAPY Vol. 14, No. 1, July 2006
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a production.
Once again, in the AdCMVGFP or AdTK-treated mice
the majority of the detected IFN-a corresponded to the
IFN-a5 gene (8 of 15 cloned sequences), indicating a
selective induction of this particular IFN-a gene (data not
shown).
These in vivo results imply that systemic adenovirus
administration in mice causes the activation of the type I
IFN system in DC.131
FIG. 2. In vivo induction of type I IFN in mouse DC by
recombinant adenovirus. Mice enriched in splenic DC
by pretreatment with sFLT-3L given by hydrodynamic
delivery 7 days prior to the experiment were iv
injected with 108 pfu AdCMVGFP or saline as control.
Spleens were harvested 24 h later and mRNA was
obtained from mPDCA-1 CD11c+ or mPDCA-1+
immunomagnetically sorted cells. Results represent
quantitative RT-PCRs measuring IFN-a and IFN-h
mRNA in comparison to h-actin from three experi-
ments independently performed.
ARTICLE doi:10.1016/j.ymthe.2006.02.015IFN-A Does Not Interfere with Gene Transfection of
Adenoviral Vectors
If exposure to adenoviral vectors induces IFN-a and
IFN-h, this event could potentially interfere with their
ability to infect and deliver genes to target cells.
However, as shown in Fig. 3A, exposure to serial
concentrations of human IFN-a2 from 100 to 5000
IU/ml for 24 h was unable to inhibit gene transfer to
HeLa cells by AdCMVGFP at various m.o.i. However,
using a recombinant defective Semliki Forest virus
encoding h-Gal (SFVLacZ) as a control, we observed a
very strong (nearly 100%) inhibition of transgene
expression in those HeLa cells infected with SFVLacZ
(Fig. 3B).
The in vitro effects shown in Fig. 3A suggest that
infection with adenovirus in vivo, although inducing IFN-
a and -h, would not interfere with adenoviral infection or
gene transfection. This is relevant either for sequential
repetition of adenovirus doses or for conditional repli-
cative adenovirus used in cancer treatment.
To explore this issue, we pretreated C57BL/6 mice
intravenously with 108pfu of AdCMVGFP or AdCMV-
LacZ 24 h before iv administration of a replication-
competent adenovirus encoding luciferase (AdWTLuc).
Using this route of administration, most adenoviral-
mediated gene expression is detected in the liver. At
different time points, we measured the expression of
luciferase by in vivo detection of light emission after
the intraperitoneal injection of the substrate d-luci-
ferin. Consistent with the in vitro results, the intra-132venous injection of two different adenoviral vectors
did not reduce the infectivity and gene transfer of
another adenoviral vector administered 24 h later
(Fig. 3C). Our results are interpreted in the sense
that the type I IFN induced by the adenovirus vectors
does not interfere with subsequent adenoviral gene
transfer in the liver in vivo. This does not preclude
that such IFN-a and -h could be relevant for other in
vivo effects of gene therapy with recombinant adeno-
viruses.
IFN-A Does Not Interfere with Adenovirus Replication
in Vitro
To address whether viral replication was affected by
type I IFN, we studied the influence of this molecule on
the ability of the wild-type adenovirus (AdWT) to
propagate its cytopathic effect on monolayers of per-
missive cells (human cervical cancer HeLa cells). We
designed the experimental conditions (low viral load
and late time points of evaluation) to ensure that the
reduction in the cell number is dependent on viral
replication and on cell-to-cell spread in the monolayers.
Cytopathic effects of adenovirus were not altered by
IFN-a (Fig. 4A), while this cytokine totally decreased the
cytopathic effect of EMCV over a wide range of
concentrations (Fig. 4B).
Therefore if adenovirus induced the release of IFN-a
and -h when given to human subjects, it would be not
expected to interfere acutely with adenoviral replication
or gene transfer.MOLECULAR THERAPY Vol. 14, No. 1, July 2006
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FIG. 3. IFN-a does not interfere with in vitro and in vivo
gene transduction with adenoviral vectors. (A) HeLa
cells were infected with AdCMVGFP (m.o.i. 500) with
or without human IFN-a2 at 5000 IU/ml. EGFP
expression was quantified by FACS in gated viable
cells. (B) As a positive control for the inhibitory effects,
a SFV vector carrying the LacZ gene (SFVLacZ) was
used to infect HeLa cells in the presence or absence of
500 IU/ml IFN-a, as indicated. The expression of the
LacZ gene was visualized by X-Gal staining and
microscopy. Baseline: uninfected cells. (C) C57BL/6
mice were intravenously injected with 108 pfu of
AdCMVLacZ, AdCMVGFP, or saline as control (n = 10
per group). Twenty-four hours later, mice were
injected intravenously with 108 pfu of a replication-
competent adenovirus expressing luciferase (AdWT-
Luc). The luciferase activity was measured in vivo 48 h
later using an in vivo imaging system. The bars
represent the light emission (photons/s F SD) in the
liver of mice that were previously ip injected with the
luciferase substrate d-luciferin. Results are representa-
tive of two independent experiments.
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from Human Peripheral Blood Leukocytes
Defective adenoviruses encoding different transgenes are
being used for cancer immunotherapy both in animal
models and in the clinic. To address if exposure of
human beings to first-generation adenoviral vectors
would activate the type I IFN system, we purified
mononuclear cells from the peripheral blood of six
healthy donors. RNA was extracted from such cells
before as well as 6 and 24 h after exposure to AdCMV-
LacZ at m.o.i. 500. We quantified IFN-a and IFN-h by
quantitative RT-PCR.
Indeed, both IFN-a and -h mRNAs were induced in all
six cases (Fig. 5). We confirmed the presence of type I IFN
activity in the 24-h culture supernatant by functional
bioassays (data not shown).MOLECULAR THERAPY Vol. 14, No. 1, July 2006
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scribed IFN-a genes in response to adenovirus in the
human system: IFN-a1/13 in four cases and IFN-a5 in the
other two cases (Fig. 5).
Type I IFN is Detected in the Sera from Human
Patients after Intratumoral Injection of Recombinant
Adenovirus
The in vitro observations in human leukocytes indicated
that the type I IFN system is induced by recombinant
adenoviral vectors in human beings. It could be inferred
that adenovirus administration to human subjects
would lead to IFN-a and IFN-h production. To explore
this issue, we measured the presence of type I IFN with a
functional bioassay in the sera of two human patients
from a gene therapy clinical trial. These two patients133
FIG. 4. In vitro replication of adenovirus is not interfered with by IFN-a. The
viability of Huh-7 cells incubated with or without IFN-a (500 IU/ml) afte
infection with increasing doses of (A) wild-type serotype 5 adenovirus or (B
EMCV is presented. Four days after infection, cells were quantified and
compared with uninfected cultures using the crystal violet method. The
percentage of surviving cells is displayed as the mean F SD in quadruplicate
wells. Similar results were obtained at later time points.
ARTICLE doi:10.1016/j.ymthe.2006.02.015
134r
)FIG. 5. Human leukocytes transcribe IFN-a and -h in response to adenoviru
exposure. Real-time RT-PCR quantification of IFN-a and IFN-h resulting from in
vitro exposure of human PBMC from six healthy donors to AdCMVLacZ a
m.o.i. 500 at the given time points. The most frequently transcribed IFN-a
gene is shown inside the 24-h bar as the number of sequences (% and
fraction) among the sequenced colonies.had received 3  1012 viral particles of a recombinant
adenovirus encoding thymidine kinase (AdTK) adminis-
tered as a single ultrasound-guided injection inside
hepatocellular carcinoma lesions [24]. As can be seen
in Fig. 6, type I IFN was undetectable in the baseline
serum samples of these two patients, but readily
detected 24 h after intratumoral adenoviral treatment,
although levels fell in samples drawn 1 day later.
Interestingly, transgene expression in these patients
has been recently documented by positron emission
tomography (PET) in the malignant lesions [24]. Some
spill of viral particles had taken place from the injected
tumors into the bloodstream, since 5 min after adeno-
viral injection quantitative PCR detected 1.2  105 and
5.7  104 adenoviral DNA copies/ml in serum samples
from each patient (not shown).
As a whole, the ability of adenoviral vectors to induce
type I IFNs should be taken into account as this cytokine
could substantially modify both the therapeutic and the
side effects of any given gene therapy regime.
DISCUSSION
The main conclusion of this study is that adenoviral
vectors activate IFN-a and IFN-h synthesis from DC,whereas paradoxically adenoviruses are not affected by
the activity of this cytokine with regard to gene transfer
or replication.
Dendritic cells behave as sentries of the immune
system [26]. Many DC subpopulations with different
phenotypic features are scattered throughout lymphoid
and nonlymphoid tissues [27]. By means of sensing
pathogens through innate mechanisms [14], they are
key players in the initiation of the innate and adaptive
immune response against viral infections.
Viral vectors such as those commonly used in gene
therapy are not an exception and they have been shown
to activate DC both to produce proinflammatory cyto-
kines and to mediate productive antigen presentation to
T lymphocytes [28–30]. Viruses often encode genes that
restrain the activation/maturation of DC to inhibit the
antiviral immune response at its very beginning [31,32].
In the past 5 years a specific DC subpopulation has
been extensively studied as the main cell subtype
responsible for the activity performed by the until
recently elusive natural interferon-producing cells [33].
These cells are named plasmacytoid dendritic cells.
Detection of viruses by means of TLRs induces a highMOLECULAR THERAPY Vol. 14, No. 1, July 2006
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FIG. 6. Type I IFN is detected in the sera from human hepatocellular
carcinoma patients after intratumoral injection of recombinant adenovirus
encoding TK (AdTK). Biofunctional type I IFN concentrations assessed in serum
samples from two patients who had received an ultrasound-guided injection
of 3  1012 viral particles of AdTK inside a intrahepatic hepatocellular
carcinoma lesion are presented. Peripheral blood samples were drawn either
immediately before or 24 and 48 h after viral injection as indicated.
ARTICLEdoi:10.1016/j.ymthe.2006.02.015output of IFN-a and -h from these pDC both in humans
and in mice [14]. Accordingly, it has been proposed that
this cell population plays a crucial role in antiviral
defense.
Our experiments with cultures enriched in those cells
show that recombinant adenoviruses trigger IFN-a and
IFN-h biosynthesis both from pDC differentiated in sFLT-
3L cultures [22] and from pDC sorted out from mouse
splenocytes. It was observed that such a phenomenon did
not require adenoviral transfection, which was found to
be extremely inefficient in this particular subset of DC, as
opposed to the relatively efficient gene transfection
reported for mDC [34,35]. Inefficiency of gene transfer
by adenovirus to pDC has been also observed in a recent
report [36] and is reminiscent of the resistance of this cell
type to viral infection with only a few exceptions [14].
Adenoviruses are known to trigger mDC maturation
both in mice and in human beings [28–30] through an
activity mediated by the capsid knob protein and viral
DNA [37]. Very recently it has been found that human
DC such as those differentiated from human monocytes
with GM-CSF and IL-4 produce IFN-a in response to
incubation with recombinant adenovirus and other viral
vectors such as retrovirus and lentivirus [35].
From the point of view of translational gene therapy
with adenovirus these findings are very important, since
type I IFNs are readily detected in DC obtained from mice
that have been exposed to adenovirus in vivo. Given theMOLECULAR THERAPY Vol. 14, No. 1, July 2006
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was a potential for self-interference. Contrary to our
expectations, we found that first-generation defective
adenoviruses and replication-competent adenoviruses
were not interfered with by IFN-a either in vitro or in
vivo. Resistance of adenovirus to IFN-a has been reported
in the literature [38] and attributed to activities encoded
in the E1a and E3 regions [39]. Deletion of E3 and E1a in
our defective adenoviruses seems to question this and
suggests that other factors might exist to explain the
observed resistance of adenovirus to the type I IFN
system.
Another practical point to be considered is that many
actions attributed to immune-potentiating transgenes
(such as cytokines) could result from additive or syner-
gistic effects of the transgene product acting in conjunc-
tion with type I IFN. Although experiments set up to
define the role of each therapeutic transgene have been
controlled with empty adenoviral vectors or vectors
encoding reporter genes, the need of transgene-inde-
pendent mechanisms for the therapeutic effects has been
overlooked. Experiments in type I IFN receptor KO mice
[7] and the recent availability of a monoclonal antibody
blocking this receptor [40] will address this possibility in
the future.
The multiplicity of type I IFN genes in the genome still
defies explanation. In mice there is a single gene
encoding IFN-h and multiple genes encoding 17 IFN-a
subtypes including 4 pseudogenes with subtle sequence
differences among them [41]. In humans there is also a
single gene for IFN-h as well as 13 genes encoding
different IFN-a subtypes plus 3 pseudogenes [2] along
with another member of the family named IFN-N [2]. A
PCR cloning technique set up to study the IFN-a genes
involved showed that IFN-h and IFN-a5 are the type I IFN
transcripts activated by adenovirus in mouse DC.
Although in our hands IFN-a1/13 and IFN-a5 are the
predominant subtypes in humans, nomenclature corre-
spondences with rodents are not possible, since gene
duplication [2] has occurred independently in primates
[42], and therefore subtype numbers merely tend to
reflect the arbitrary order of discovery. The reason IFN-
a5 is so selectively induced by adenovirus in the mouse
system is enticing and deserves further study. According
to previous reports [43], there is a likely involvement of a
first wave of autocrine IFN-h in the induction of IFN-a.
Human leukocytes such as those met by adenovirus
during treatment of patients in clinical trials with
adenoviral vectors also produce IFN-a and IFN-h. This
finding indicates that the ability of adenovirus to induce
type I IFN is not species-specific and could be an
important factor in the design and interpretation of
clinical trials. We took advantage of the availability of
serum samples from patients who had received an
injection of adenovirus encoding thymidine kinase to
explore this issue [24]. Indeed, type I IFN was detectable in135
ARTICLE doi:10.1016/j.ymthe.2006.02.015serum after adenovirus injection into liver tumor lesions.
Recorded data showed that a part of the adenoviral dose
given inside liver tumors reached the bloodstream and
viral DNA was detected in the serum of these two patients
5 min after adenoviral treatment. This is consistent with
reports that show that intratumoral treatment of adeno-
virus gives rise to a certain degree of viral spill to systemic
circulation [44]. Leukocytes including dendritic cells can
be easily reached at/from the bloodstream.
In conclusion, this study reveals that IFN-a and IFN-h
are turned on by adenoviral vectors in DC. The fact that
adenovirus itself is resistant to the immediate antiviral
actions of type I IFNs does not preclude that IFN-a could
shape a subsequent specific antiadenoviral immune
response. Moreover, innate type I IFNs elicited by viral
vectors might play a pivotal role in the therapeutic activity
attributed to several immunostimulating transgenes.MATERIAL AND METHODS
Mice and cells. Female 4- to 6-week-old C57BL/6 mice were purchased
from Harlan (Barcelona, Spain), housed in appropriate animal care
facilities during the experimental period, and handled following the
institutional guidelines required for experimentation with animals. HeLa
(human cervix carcinoma), Huh-7 (human hepatoma), and BNL (BALB/c
mice hepatoma) cell lines were cultured at 378C and 5% CO2 in DMEM
supplemented with 10% fetal calf serum (FCS) and antibiotics. All
reagents were purchased from Cambrex (Verviers, Belgium).
Recombinant virus and cell transfection. Defective recombinant adeno-
viruses AdCMVGFP [45] and AdCMVLacZ [46] were produced using
standard conditions. AdWTLuc is a replication-competent adenovirus
that expresses luciferase under the control of the endogenous adenoviral
late promoter. The reporter gene was inserted in the E3 region, replacing
the 6.7K/gp19K genes, as described by Hawkins et al. [47]. SFVLacZ [48]
and EMCV [4] were produced and titers assessed as described in each case.
LPS concentrations in adenovirus batches, including clinical grade
adenovirus, were below the detection levels of a sensitive commercial
kit that detects up to 0.15 EU/ml (Cambrex Limulus amebocyte lysate
QCL-1000). Replication-competent adenovirus contamination in
AdCMVGFP was 1:4.2  105 as assessed by the ratio of E1 versus E4 genes
measured by quantitative PCR.
DC or HeLa cells were plated at 107 cells/ml in serum-free medium and
infected for 2 h with the indicated adenovirus at m.o.i. ranging from 50 to
3000. After infection, RPMI supplemented with 10% FCS was added to the
wells and cells were subsequently incubated at 378C for 24 h. After
incubation, adenovirus-infected cells were harvested, washed three times
with saline buffer, resuspended to a cell density of 5  106 cells/ml in PBS,
and analyzed by flow cytometry (FACSCalibur; Becton–Dickinson, San
Jose, CA, USA).
Bone marrow cultures enriched in DC. Cultures of sFLT-3L-supplemented
mouse bone marrow cells were generated as described [22]. Briefly, bone
marrow cells were cultured after erythrocyte lysis at a density of 1.5  106
cells/ml in RPMI 1640, 10% FCS, 100 ng/ml sFLT3-L (R&D) for 10 to 12
days.
The phenotype of pDC was assessed by flow cytometry (FACSCalibur)
upon staining with FITC- or PE-conjugated monoclonal antibodies
against Ly6C, mPDCA-1, CD80, CD86, CD11c, CD11b, B220, CD40,
CD14, H-2Kb, and I-Ab [22] (Pharmingen). A nonreactive fluorochrome-
tagged rat monoclonal antibody was used as control.
Immunomagnetic bead separation. Mouse pDC were isolated using
immunomagnetic mPDCA-1 beads (Miltenyi Biotec, Bergisch Gladbach,136Germany). mDC were isolated from the mPDCA-1 negative fractions using
CD11c-conjugated beads (Miltenyi) according to manufacturerTs instruc-
tions using an AutoMACS device (Miltenyi). Yield and purity of each cell
separation were monitored immediately after each immunomagnetic cell
sorting procedure by immunofluorescence and FACS analysis.
Analysis of mRNA expression by quantitative real time-PCR. Total RNA
from the cells was extracted using Ultraspec Reagent (Biotex, Houston,
TX, USA). One microgram of total RNA was treated with DNase (Gibco
BRL, Paisley, UK) prior to reverse transcription with M-MLV reverse
transcriptase (Gibco BRL) in the presence of RNaseOUT (Gibco BRL).
Mouse and human IFN-a, IFN-h, and h-actin expression was measured by
quantitative real-time PCR using an ICycler and the IQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA). Aliquots of 2 Al of
the cDNA pool were used for each PCR, containing upstream and
downstream primers specific for each gene in a 20-Al final volume
(Supplementary Table 1). Degenerate primers designed to recognize all
IFN-a subtypes amplified all subtypes from both humans and mice
with similar efficiency. To determine the PCR specificity, the final PCR
products were analyzed by melting curves and electrophoresis. Results
were normalized according to h-actin quantification in the same
sample. The amount of each transcript was expressed by the formula
2ct(actin)  ct(gene), with ct the point (PCR cycle) at which the fluore-
scence rises appreciably above the background fluorescence [49].
Statistical analyses were performed using nonparametric (Kruskal–
Wallis and Mann–Whitney U) tests.
IFN-a subtypes analysis. For sequence analysis of IFN-a subtypes, RNA
extracted from the cells was treated with DNase (Gibco BRL) prior to reverse
transcription and was amplified by RT-PCR using Expand High Fidelity Taq
polymerase (Roche Diagnostics, Mannheim, Germany). IFN-a PCR prod-
ucts were cloned using the TOPO TA cloning kit (Invitrogen, Paisley, UK)
according to the manufacturer’s protocol. At least 20 clones from each
transformation were purified with the Templiphi amplification kit
(Amersham Biosciences, Barcelona, Spain). Plasmids obtained were
sequenced by fluorescence-based Taq Dye Deoxy-terminator cycle
sequencing system using the BigDye Terminator Cycle Sequencing Ready
Reactions Kit (ABI Prism, Applied Biosystems, Foster City, CA, USA) and
M13 universal primers in an automated sequencer (ABI Prism 310 genetic
analyzer; Applied Biosystems). Sequences were checked against the
GenBank database by using BLAST to determine the IFN-a subtype.
IFN-a bioassay. The antiviral activity of mouse IFN was determined by
measuring its ability to protect murine BNL cells against the cytopathic
effect of EMCV. The assay was performed in a 96-well microtiter plate.
First, 2  104 BNL cells per well were seeded in 150 Al of medium
containing serial dilutions of DC supernatants and incubated for 24 h.
EMCV (5  106 pfu per well) were added, and 24 h later the cytopathic
effect was measured by staining with crystal violet dye solution (0.5% in
1/4 v/v methanol/water). The optical density was read at 595 nm. At the
same time, serial dilutions of mouse IFN-a (PBL Biomedical Laboratories,
Piscataway, NJ, USA) were tested to obtain a standard curve. Results are
expressed as units/ml and were calculated interpolating the optical
density of each sample in the standard curve. IFN activity in human
serum samples was determined using the above conditions with HeLa
cells and serial dilutions of human IFN-a (Intron A; Schering-Plough,
Madrid, Spain) as standard curve.
Hydrodynamic injection. Hydrodynamic injections of a plasmid encod-
ing mouse sFLT-3L were performed in a volume of 100 ml/kg using a 27-
gauge needle at a rate of 0.4 ml/s as previously described [25]. Increases in
DC numbers were checked in the spleen of a sample of the mice.
In vivo detection of luciferase activity. C57BL/6 mice were pretreated
intravenously with 108 pfu of AdCMVGFP or AdCMVLacZ 24 h before
being intravenously injected with a replicative adenovirus encoding
luciferase. Forty-eight hours later mice were anesthetized by intraperito-
neal injection of ketamine (100 mg/kg) and xylazine (5 mg/kg), and their
abdomen was shaved. The luciferase substrate d-luciferin (3 mg dissolved
in 100 Al PBS) was administered intraperitoneally (In Vivo ImagingMOLECULAR THERAPY Vol. 14, No. 1, July 2006
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emission was quantified using an in vivo imaging system based on a CCD
camera (IVIS; Xenogen) [50]. The activity is represented as photons/s.
Viral cytotoxicity assays. The cytotoxicity of adenovirus was analyzed
by crystal violet staining of virus-infected cell monolayers. Huh-7 cells
were seeded at a density of 5  103 cells/well in 96-well plates. The
following day, cells were infected with increasing amounts of AdWT or
EMCV, starting with very low m.o.i. (0.12 in the case of AdWT) to
ensure that the destruction of the monolayer depended on viral
replication. At least 4 days later, dead cells were removed by PBS
washes. The unbound dye was removed by washing several times with
water, and the plate was air-dried. Finally, the crystal violet incorpo-
rated in the cellular DNA was dissolved in 10% acetic acid and the
absorbance at 595 nm was measured in a spectrophotometer.
Patients. Clinical-trial-authorized serum samples stored for 8 months at
808C were taken from two advanced hepatocellular cancer patients
before and after intratumoral treatment with 3  1012 viral particles of
a clinical-grade adenovirus manufactured and quality controlled by
Molecular Medicine LLC (Los Angeles, CA, USA) encoding the herpes
virus thymidine kinase (AdTK) [24]. Transgene expression was con-
firmed in these patients by PET imaging as recently published [24].
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